PARP1 and asthma: We showed that a post-ovalbumin (OVA) challenge administration of a noncompetitive PARP inhibitor, termed thieno [2,3-c]isoquinolin-5-one (TIQ-A), is more efficacious than a prophylactic administration of the drug in reducing OVA-specific IgE production, Th2 responses, and airway resistance in an animal model of asthma [12].